{
}
Cytokinetics (CYTK) shares soared after Barclays issued an Overweight rating with a $55 price target, driven by expectations of FDA approval for aficamten. Analysts forecast an average target price of $78.68, indicating a potential upside of 95.25% from the current price of $40.30, with a consensus rating of 1.9 suggesting strong investor confidence. GuruFocus estimates a projected GF Value of $209.65, reflecting a potential upside of 420.22%.
Deutsche Bank has upgraded Evotec (EVO) from "Sell" to "Hold" and raised its price target from EUR 4 to EUR 7, following the company's new guidance for 2025. Despite lower-than-expected adjusted EBITDA projections, the guidance is seen as a solid foundation for valuation, with analysts forecasting an average target price of $6.00, indicating a potential upside of 46.88%. Evotec reported strong Q4 2024 results, with significant revenue growth and operational leverage, while also achieving EUR 40 million in run rate savings through a priority reset.
Established vendors like Nokia, Ericsson, and Huawei dominate the private 5G market, but startups such as Celona and Vilicom are gaining traction. Celona has over 100 customers and is being considered by John Deere, while Vilicom recently deployed a 4G LTE network for Bristol-Myers Squibb in Dublin. Other emerging players like Highway 9, with MIT as a key client, are also making their mark in the industry.
UBS analysts have maintained a Neutral rating on Bristol-Myers Squibb (BMY) with a price target of $60, noting the stock is currently trading below its fair value. Despite concerns over Cobenfy's recent prescription stagnation, UBS projects significant sales growth for the product, estimating $18-$21 million in Q1 2025 and $150-$170 million for the year. Additionally, Bristol-Myers has received expanded approvals for its CAR-T therapy and entered an agreement to acquire 2seventy bio for $286 million, reflecting its ongoing commitment to innovation and shareholder value.
UBS has maintained a Neutral rating on Bristol-Myers Squibb, setting a target price of €60, as the company trades below its Fair Value. Despite recent stagnation in Cobenfy prescriptions, analysts project potential sales growth, estimating €18-21 million for Q1 2025 and €150-170 million for the full year. Additionally, Bristol-Myers has received expanded approvals for its CAR-T therapy and entered an agreement to acquire 2seventy bio for €286 million, while continuing to deliver dividends reflecting its financial health.
UBS has maintained a Neutral rating on Bristol-Myers Squibb (BMY) with a price target of $60, noting the stock is currently trading below its fair value. Despite recent stagnation in prescriptions for Cobenfy, analysts project significant sales growth, estimating $18-$21 million for Q1 2025 and $150-$170 million for the full year. Additionally, the European Commission has expanded approvals for Breyanzi and Opdivo-Yervoy, while the company plans to acquire 2seventy bio for $286 million, reflecting its ongoing commitment to innovation and shareholder value.
The High Potency Active Pharmaceutical Ingredients Market is experiencing significant growth, driven by increased demand, technological advancements, and a broadening customer base. A comprehensive report provides insights into market trends, competitive landscape, and future opportunities, highlighting key players such as Lonza and Novartis. The analysis covers various segments, production technologies, and applications, offering a detailed outlook on the industry's trajectory through 2032.
Light Horse Therapeutics has secured $62 million in Series A financing and formed a partnership with Novartis, which includes a $25 million upfront payment and potential milestone payments of up to $1 billion. The biotech aims to revolutionize drug discovery with its genetic editing-based platform, initially focusing on challenging oncology targets while exploring other therapeutic areas in the future.
Light Horse Therapeutics has launched with $62 million in Series A financing led by Versant Ventures, alongside partners including Novartis. The company focuses on developing small molecule therapeutics using a precision gene editing platform to tackle challenging oncology targets, with potential for broader applications. The collaboration with Novartis includes a $25 million upfront payment and up to $1 billion in milestone payments, aiming to create first-in-class therapies.
Light Horse Therapeutics has launched with a $62-million series A financing and a collaboration with Novartis potentially worth over $1 billion. The San Diego-based biotech employs a "function-first" approach to drug discovery, focusing initially on oncology targets while integrating precision genome editing techniques. The partnership includes a $25-million upfront payment and opportunities for significant R&D and sales milestones.
Bristol-Myers Squibb Co
Companies
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
Cytokinetics shares rise after Barclays issues bullish overweight rating
21:56 24.04.2025
Deutsche Bank upgrades Evotec rating and raises price target to seven euros
Euro
United States Dollar
Bristol-Myers Squibb Co
Novo Nordisk A/S
Sandoz Group AG
Evotec SE
Pfizer Inc.
BAYER
DEU
Show more
10:45 24.04.2025
emerging players in the private 5G market challenge established vendors
13:20 02.04.2025
ubs maintains neutral rating on bristol myers with 60 dollar target
15:46 27.03.2025
ubs maintains neutral rating on bristol myers with target price of sixty euro
15:31 27.03.2025
ubs maintains neutral rating on bristol myers with price target of sixty dollars
15:31 27.03.2025
high potency active pharmaceutical ingredients market trends and future growth prospects
Merck & Co., Inc.
Roche Diagnostics AG
Eli Lilly and Company
Teva Pharmaceutical Industries Ltd
BASF AG
Novartis International AG
Lonza Group AG
Bristol-Myers Squibb Co
Cambrex Corporation
Seqens
Pfizer Inc.
Sanofi Aventis SA
Bayer AG
CARBOGEN AMCIS AG
Alice Mutum
Viju Shah
Show more
10:02 26.03.2025
light horse therapeutics secures 62 million and partners with novartis
United States Dollar
Bristol-Myers Squibb Co
Novartis AG
ABBVIE
ARE
USA
John Tallarico
Markus Renschler
Show more
13:38 10.01.2025
light horse therapeutics launched with 62 million funding and novartis partnership
United States Dollar
Bristol-Myers Squibb Co
Novartis AG
ABBVIE
ARE
JPN
USA
Ben Cravatt
Brian Liau
Markus Renschler
John Tallarico
Nathanael Gray
Show more
13:38 10.01.2025
light horse therapeutics secures funding and partnership with novartis
United States Dollar
Bristol-Myers Squibb Co
Novartis AG
ABBVIE
USA
Ben Cravatt
Laure Escoubet
Brian Liau
Markus Renschler
John Tallarico
Nathanael Gray
Show more
16:13 09.01.2025
Trending
Subcategory
Corporate News
Industry Trends
Stock Market Updates
Finance Mergers & Acquisitions
Retail and Consumer Goods
Global Financial Events
AI Innovations
Industry Mergers & Acquisitions
Startups & Entrepreneurship
Banking Regulations
Central Bank Actions
Funding Rounds & Investments
Market Analysis and Predictions
Supply Chain Management
Global Trade Developments
CEO Changes
AI & Automation Regulations
Government Policies
Government Economic Policies
Inflation and Monetary Impact
Countries:
Companies:
NVIDIA Corporation
Huawei Technologies CO. Ltd.
Apple Inc.
Wells Fargo & Company
The Goldman Sachs Group, Inc.
Tesla, Inc.
Barclays PLC
BNP Paribas SA
Bank of America Corporation
Citigroup Inc.
Microsoft Corporation
Morgan Stanley
Amazon.com, Inc.
HSBC HOLDINGS
Erste Group Bank AG
Berkshire Hathaway Inc.
American Express Co
UBS Group AG
DEUTSCHE TELEKOM
Banco Santander, S.A.
Currencies:
United States Dollar
Euro
British Pound Sterling
Swiss Franc
Indian Rupee
Chinese Yuan
Japanese Yen
United Arab Emirates Dirham
Offshore Chinese Yuan
Saudi Riyal
Australian Dollar
Hong Kong Dollar
Swedish Krona
Canadian Dollar
Russian Ruble
Brazilian Real
South Korean Won
Norwegian Krone
Egyptian Pound
Turkish Lira
People: